Cystic Fibrosis Clinical Trial
Official title:
Effects of Aerobic Interval Training on Glucose Tolerance in Children and Adolescents With Cystic Fibrosis: Randomized Controlled Trial
The purpose of this study is to investigate the effects of aerobic exercise on glucose
tolerance in individuals with cystic fibrosis.
The hypothesis is that performing High Intensity Interval Training glucose tolerance will
improve in individuals with cystic fibrosis.
This is a controlled, randomized, and single blind trial. The first researcher (P1) will be
responsible for the randomization process; the second researcher (P2) will be responsible for
the evaluations and reevaluations. This evaluator (P2) will be "blind", meaning that for him
it is totally unknown in which group each patient will be insert; and the third researcher
(P3), will be responsible for statistical analysis.
Individuals will be recruited at the Child and Adolescent Health Care Unit of the Onofre
Lopes University Hospital (HUOL) and in the Department of Physical Therapy of the State
University of Paraíba (UEPB), Campina Grande - PB, Brazil. They will be evaluated at the
Physical Therapy Department of the Federal University of Rio Grande do Norte (UFRN), Natal -
RN, Brazil and in the Department of Physical Therapy of the State University of Paraíba
(UEPB), in the city of Campina Grande - PB. A pilot study will be carried out and the sample
calculation will be done with the data collected to reach a statistical power of 80% and a
level of significance of 0.05%. Allocation in the groups will be performed by P1, randomly in
blocks by the volunteer being prepubertal or pubertal. The R Core Team software (2015) will
be used for this process.
In this study two groups will be considered: control group (CG) and aerobic exercise group
(AEG). The CG will be submitted to educational intervention. The AEG will be submitted to the
same educational intervention and to the High Intensity Interval Training.
After the pilot study, the patients will be evaluated to obtain information on severity and
exacerbation of the disease, quality of life, metabolic evaluation, anthropometric measures,
and lung function. All evaluations will be carried out at the same day period (morning).
Researcher two (P2) will be responsible for the evaluation and reassessment procedure of the
individuals, hence he will be "blind" meaning that for him it is totally unknown in which
group each patient will be or was inserted. Individuals will be instructed to do not perform
physical activity in the day before the evaluations. After this step, individuals will be
randomly distributed in CG or EAG.
Volunteers from both groups will be instructed to maintain nutritional, drug and secretion
care. In addition, they will be instructed to do not get engaged in any other kind of
physical activity. The intervention will last 2 months and will occur 3 times a week until a
total of 24 sessions. After the intervention ends and after the 8-week follow-up, all
volunteers will be reevaluated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |